Jl Clua-Espuny | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Assist Prof. Dr. Jl Clua-Espuny | Personalized Medicine | Best Researcher Award

Ebrictus Group at IDIAP Jordi Gol | Spain

Assist. Prof. Dr. JL Clua-Espuny is a distinguished academic and healthcare professional with extensive experience in medicine, primary healthcare, and medical education. He has served in various leadership and academic roles across prestigious institutions, including Universitat Rovira i Virgili, Universidad Miguel Hernández de Elche, and the Institut Català de la Salut. His expertise spans family medicine, health policy, and clinical research, with a strong commitment to improving patient care and medical training. Throughout his career, he has mentored numerous doctoral candidates, contributed to healthcare policy initiatives, and advanced research in cardiovascular diseases, primary care innovation, and public health strategies.

Publication Profile 

Orcid

Education 

Assist. Prof. Dr. JL Clua-Espuny holds multiple advanced degrees, including a Doctorate in Medicine and a Master’s in Primary Care from Universidad Miguel Hernández de Elche. He also completed specialized master’s programs in Health Economics and Healthcare Management from the University of Barcelona and advanced training in Quality Management at Universidad Autonoma de Barcelona and Fundació Avedis Donabedian. Additionally, he earned postgraduate diplomas in Primary Care Management and Quality Evaluation Methodologies and holds dual degrees in Medicine and Philosophy/Psychology from the University of Barcelona. His academic path reflects a dedication to integrating medical, administrative, and research excellence to improve healthcare delivery systems.

Experience 

Assist. Prof. Dr. JL Clua-Espuny career spans healthcare, academia, and research. He served as Director of Primary Care at the Institut Català de la Salut, Vice-President of the Health Council in Tortosa, and Coordinator of Health Plans for the Catalan Health Service. In academia, he has been a professor and tutor at Universitat Rovira i Virgili and Universidad Miguel Hernández de Elche, guiding numerous doctoral and master’s theses. His research affiliations include the Institut Recerca IDIAP Jordi Gol. He has combined clinical practice, academic instruction, healthcare leadership, and policy planning, contributing significantly to primary care innovations and medical education reforms in Spain.

Awards and Honors 

Assist. Prof. Dr. JL Clua-Espuny has received multiple honors for his contributions to medicine, education, and research. He earned the Premio Extraordinario de Doctorado for academic excellence and has been recognized for advancing primary healthcare research and education in Catalonia. His leadership roles in healthcare institutions and medical associations highlight his influence in shaping health policy and service delivery. He has been invited to collaborate in national and regional healthcare planning, reflecting his reputation as an expert in primary care management and cardiovascular health research. His mentorship of numerous doctoral theses further illustrates his commitment to academic excellence and professional development.

Research Focus 

Assist. Prof. Dr. JL Clua-Espuny research centers on primary healthcare, cardiovascular disease prevention, public health interventions, and healthcare quality improvement. He has led and collaborated on projects investigating atrial fibrillation, ischemic stroke, heart failure, and healthcare service optimization. His work often bridges clinical practice with public health policy, emphasizing early detection, risk stratification, and health outcomes in community settings. He has contributed extensively to evaluating the economic impact of chronic diseases, vaccination strategies, and integrated care models. His multidisciplinary approach combines epidemiology, clinical research, and healthcare management to develop innovative strategies for improving patient outcomes and enhancing primary care systems.

Publication Top Notes

Estado de malnutrición como factor pronóstico de eventos cardiovasculares adversos mayores (MACE) en los pacientes con fibrilación auricular

Recent-onset atrial fibrillation: challenges and opportunities

Integrating Lung Ultrasound and the HEFESTOS Score in the Outpatient Heart Failure Management: A Prospective Cohort Study

Prediction of Major Adverse Cardiovascular Events in Atrial Fibrillation: A Comparison Between Machine Learning Techniques and CHA2DS2-VASc Score

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Abordaje extrahospitalario y hospitalario del ictus en fase aguda

Detección precoz de la fibrilación auricular a través de alteraciones en la onda P en el electrocardiograma (ECG) y la disfunción auricular en el ecocardiograma transtorácico (ETT) (póster)

Evidence Gaps and Lessons in the Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)

Evidence Gaps and Lessons in Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)

The Predictive Potential of C-Peptide in Differentiating Type 1 Diabetes From Type 2 Diabetes in an Outpatient Population in Abu Dhabi.

Sex Disparities in the Direct Cost and Management of Stroke: A Population-Based Retrospective Study

Prognostic Significance of Lung Ultrasound for Heart Failure Patient Management in Primary Care: A Systematic Review

Conclusion

Given his extensive research supervision, academic leadership, healthcare experience, and contributions to primary care and public health research, Assist. Prof. Dr. JL Clua-Espuny is highly suitable for the Best Researcher Award. His decades of service, combined with scientific innovation, educational mentorship, and healthcare leadership, position him as a strong candidate. By expanding global research collaborations and enhancing the international dissemination of his work, he could further elevate his impact in the field.

Maria Garrido | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Dr. Maria Garrido | Personalized Medicine | Women Researcher Award

Doctor at Hospital Universidtario 12 de octubre-Universidad Complutense de Madrid | Spain

Dr. Maria Garrido is a physician-scientist specializing in pathology and translational oncology with a focus on melanoma and cutaneous lymphomas. She earned her medical degree from the University of Granada and her PhD in Health Sciences and Biomedicine from Universidad Complutense de Madrid. With extensive international experience at the University of California San Francisco and Memorial Sloan Kettering, her research has contributed to landmark discoveries in oncogenes, fusion kinases, and tumor biomarkers. She currently works in dermatopathology and oncology research, collaborating with leading groups in Europe and internationally to advance personalized cancer diagnostics and therapeutic strategies.

Publication Profile 

Orcid

Education 

Dr. Maria Garrido obtained her medical degree in Medicine and Surgery from the University of Granada. She pursued her residency in Anatomical Pathology at Hospital Universitario 12 de Octubre, Madrid, and later completed a PhD in Health Sciences and Biomedicine at Universidad Complutense de Madrid. Complementing her medical and scientific training, she earned a Master’s in Clinical Management, Medical, and Healthcare Leadership from Universidad Tecnológica. Her academic formation integrates rigorous clinical foundations with molecular oncology research, allowing her to bridge patient care and translational science. She has continued to enhance her expertise through national and international academic fellowships.

Experience 

Dr. Maria Garrido has served as a resident and clinical specialist in pathology at major Spanish hospitals, including Hospital 12 de Octubre, Hospital General de Móstoles, and Clinic Hospital of Barcelona. Internationally, she was a fellowship researcher at UCSF and Memorial Sloan Kettering, contributing to melanoma genetics and translational oncology. She has collaborated on groundbreaking discoveries, including oncogenes in uveal melanoma and fusion kinases in Spitz tumors. Currently, she is part of the dermatopathology and oncology research group at Hospital Universitario 12 de Octubre, Madrid, where she advances studies on melanoma, lymphomas, molecular biomarkers, and diagnostic innovations in cutaneous oncology.

Awards and Honors 

Dr. Maria Garrido has received notable recognition for her research contributions. She was awarded a mobility fellowship by the Spanish Ministry of Science and Innovation for professional development in computational pathology at Queen’s University, Belfast. Her discoveries, including the GNA11 oncogene and fusion kinases in melanocytic tumors, have been published in high-impact journals such as the New England Journal of Medicine, Nature Communications, and Nature Genetics. Her contributions to the field of melanoma genetics have been cited worldwide, shaping the understanding of tumor biology. She continues to be honored through invitations to collaborate on international research initiatives and networks.

Research Focus 

Dr. Maria Garrido research focuses on the molecular pathology of melanoma and cutaneous lymphomas. She has made significant contributions to identifying oncogenes such as GNA11 and GNAQ, which account for most uveal melanomas, and discovering kinase fusion proteins in Spitz tumors. Her work also includes genetic studies on desmoplastic melanoma highlighting NFKBIE mutations. More recently, she has contributed to refining the classification of cutaneous lymphomas and identifying new biomarkers to guide diagnosis, prognosis, and therapeutic response. Her approach integrates pathology, molecular biology, and translational medicine to improve personalized treatment strategies and enhance patient outcomes in oncology and dermatopathology.

Publication Top Notes

Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances

Acute sarcoidosis as a harbinger for pancreatic adenocarcinoma

TERT promoter mutation in sebaceous neoplasms

Orbital Solitary Fibrous Tumor: Four Case Reports—Clinical and Histopathological Features

Conjunctival Tarsal Actinic Keratosis Treated with Interferon Alfa-2b: A Rare Case Report and Literature Review

SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma